A Phase III trial of RP-G28.
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs RP G28 (Primary)
- Indications Lactose intolerance
- Focus Registrational; Therapeutic Use
- Sponsors Ritter Pharmaceuticals
- 02 May 2017 According to a Ritter Pharmaceuticals media release, the company is planning an end of phase 2 meeting with the FDA to present and discuss the plan of this trial. This trial will support NDA submission. The company will discuss the final features of this trial with the FDA at upcoming meeting.
- 12 Apr 2017 According to a Ritter Pharmaceuticals media release, the company anticipates the initiation of the trial in the first half of 2018 and plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance.
- 01 Mar 2017 New trial record